CTLA-4 blockade: therapeutic potential in cancer treatments

Enhancing or prolonging T-cell activation by monoclonal antibodies (mAbs) blocking negative signaling receptors such as CTLA4 is one approach to overcoming tumor-induced immune tolerance. Ipilimumab and tremelimumab inhibit CTLA4, prolonging antitumor immune responses and leading to durable anti-tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarhini, Ahmad A, Iqbal, Fatima
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895779/
https://www.ncbi.nlm.nih.gov/pubmed/20616954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895779/
https://www.ncbi.nlm.nih.gov/pubmed/20616954

Ejemplares similares